NVCT

Nuvectis Pharma, Inc. Common Stock [NVCT] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NVCT Stock Summary

Top 10 Correlated ETFs

NVCT


Top 10 Correlated Stocks

NVCT


In the News

08:00 29 Mar 2024 NVCT

Nuvectis Pharma to Present at the 36th Annual Roth Conference

FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will present at the 36th Annual Roth Conference.

08:32 29 Mar 2024 NVCT

Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

08:00 29 Mar 2024 NVCT

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

08:00 29 Mar 2024 NVCT

Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 42nd Annual J.P. Morgan Healthcare Conference, as follows:

11:18 29 Mar 2024 NVCT

Down -36.49% in 4 Weeks, Here's Why You Should You Buy the Dip in Nuvectis Pharma, Inc. (NVCT)

The heavy selling pressure might have exhausted for Nuvectis Pharma, Inc. (NVCT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

07:30 29 Mar 2024 NVCT

Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation

Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the 2023 Cantor Global Healthcare Conference Corporate Presentation, as follows:

08:03 29 Mar 2024 NVCT

Nuvectis: Early Stage Company That's Low On Cash

Nuvectis is developing precision medicines for cancer patients, with lead asset NXP800 targeting ARID1a-mutated ovarian cancer. Preclinical trials have shown strong antitumor activity of NXP800, including in cisplatin resistant patients. NVCT also has a second asset, NXP900, which has shown significant single-agent activity in squamous cell cancer models.

08:00 29 Mar 2024 NVCT

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

08:44 29 Mar 2024 NVCT

New Strong Buy Stocks for July 10th

CRBG, LSF, SMWB, NVCT and WT have been added to the Zacks Rank #1 (Strong Buy) List on July 10, 2023.

09:55 29 Mar 2024 NVCT

Here's Why Momentum in Nuvectis Pharma, Inc. (NVCT) Should Keep going

Nuvectis Pharma, Inc. (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

NVCT Financial details

Company Rating
Sell
Market Cap
157.12M
Income
-22.21M
Revenue
4.1M
Book val./share
0.7
Cash/share
1.1
Dividend
-
Dividend %
-
Employees
13
Optionable
No
Shortable
Yes
Earnings
06 May 2024
P/E
-7.43
Forward P/E
-4.78
PEG
13.75
P/S
41.54
P/B
9.84
P/C
7.55
P/FCF
-11.3
Quick Ratio
3.96
Current Ratio
3.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.4
EPS next Y
-1.74
EPS next Q
-0.4
EPS this Y
-3.38%
EPS next Y
24.05%
EPS next 5Y
-356.43%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
2.7%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
7.22%
Inst Trans
0.85%
ROA
-99%
ROE
-139%
ROC
-1.37%
Gross Margin
-181%
Oper. Margin
-537%
Profit Margin
-520%
Payout
-
Shs Outstand
17.42M
Shs Float
6.54M
-
-
-
-
Target Price
-
52W Range
6.2-18.65
52W High
-53.83%
52W Low
+38.5%
RSI
45
Rel Volume
0.29
Avg Volume
108.7K
Volume
31.15K
Perf Week
-5.03%
Perf Month
5.59%
Perf Quarter
-26.46%
Perf Half Y
-39.43%
-
-
-
-
Beta
0.334
-
-
Volatility
0.34%, 1.1%
Prev Close
-0.36%
Price
8.31
Change
0.24%

NVCT Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K
Revenue per share
000.010
Net income per share
0-1.01-1.48-1.43
Operating cash flow per share
0-0.75-1.07-1.03
Free cash flow per share
0-0.75-1.07-1.03
Cash per share
00.451.581.23
Book value per share
0-0.871.120.78
Tangible book value per share
0-0.871.120.78
Share holders equity per share
0-0.871.120.78
Interest debt per share
000.010
Market cap
41.33M41.33M94.93M129.74M
Enterprise value
41.33M35.59M74.94M110.62M
P/E ratio
-4.13K-3.21-5.05-5.83
Price to sales ratio
00637.130
POCF ratio
1.72K-4.35-7-8.13
PFCF ratio
1.72K-4.35-7-8.13
P/B Ratio
-4.13K-3.756.6810.63
PTB ratio
-4.13K-3.756.6810.63
EV to sales
00502.950
Enterprise value over EBITDA
-4.13K-2.76-3.9-4.83
EV to operating cash flow
1.72K-3.74-5.53-6.93
EV to free cash flow
1.72K-3.74-5.53-6.93
Earnings yield
0-0.31-0.2-0.17
Free cash flow yield
0-0.23-0.14-0.12
Debt to equity
0000
Debt to assets
0000
Net debt to EBITDA
00.451.040.84
Current ratio
02.413.32.75
Interest coverage
00-129.090
Income quality
-10.740.710.72
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
0040.320
Research and developement to revenue
0088.770
Intangibles to total assets
0000
Capex to operating cash flow
0000
Capex to revenue
0000
Capex to depreciation
0000
Stock based compensation to revenue
0011.460
Graham number
04.446.125.02
ROIC
11.17-1.33-1.88
Return on tangible assets
0-1.94-0.92-1.16
Graham Net
0-0.941.090.78
Working capital
-10K3.41M14.22M12.2M
Tangible asset value
-10K-11.01M14.22M12.2M
Net current asset value
-10K-11.83M14.22M12.2M
Invested capital
0000
Average receivables
0000
Average payables
0534K1.98M2.84M
Average inventory
0000
Days sales outstanding
0000
Days payables outstanding
029.9555.2244.17
Days of inventory on hand
0000
Receivables turnover
0000
Payables turnover
012.196.618.26
Inventory turnover
0000
ROE
11.17-1.32-1.82
Capex per share
0000

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.010.28000
Net income per share
-0.52-0.27-0.38-0.37-0.38
Operating cash flow per share
-0.28-0.32-0.27-0.2-0.22
Free cash flow per share
-0.28-0.32-0.27-0.2-0.22
Cash per share
1.581.051.621.371.1
Book value per share
1.120.831.341.040.7
Tangible book value per share
1.120.831.341.040.7
Share holders equity per share
1.120.831.341.040.7
Interest debt per share
0.010000
Market cap
94.93M193.03M242.39M207.59M145.27M
Enterprise value
74.94M177.57M217.79M185.53M126.15M
P/E ratio
-3.63-12.07-10.62-8.82-5.48
Price to sales ratio
637.1347.07000
POCF ratio
-27-40.41-59.37-63.99-37.73
PFCF ratio
-27-40.41-59.37-63.99-37.73
P/B Ratio
6.6815.7311.9212.4411.91
PTB ratio
6.6815.7311.9212.4411.91
EV to sales
502.9543.3000
Enterprise value over EBITDA
-11.06-43.3-37.73-30.13-18.37
EV to operating cash flow
-21.31-37.17-53.34-57.19-32.77
EV to free cash flow
-21.31-37.17-53.34-57.19-32.77
Earnings yield
-0.07-0.02-0.02-0.03-0.05
Free cash flow yield
-0.04-0.02-0.02-0.02-0.03
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
2.953.774.263.582.79
Current ratio
3.34.125.413.992.75
Interest coverage
-82.6678.87000
Income quality
0.531.180.720.550.58
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
15.980.42000
Research and developement to revenue
29.510.58000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
3.230.34000
Graham number
3.612.263.372.922.45
ROIC
-0.47-0.33-0.28-0.37-0.56
Return on tangible assets
-0.32-0.25-0.23-0.26-0.35
Graham Net
1.090.781.321.020.7
Working capital
14.22M12.27M20.33M16.69M12.2M
Tangible asset value
14.22M12.27M20.33M16.69M12.2M
Net current asset value
14.22M12.27M20.33M16.69M12.2M
Invested capital
00000
Average receivables
00000
Average payables
2.58M2.5M1.95M2.65M3.13M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
0028.1151.040
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
003.21.760
Inventory turnover
00000
ROE
-0.46-0.33-0.28-0.35-0.54
Capex per share
00000

NVCT Frequently Asked Questions

What is Nuvectis Pharma, Inc. Common Stock stock symbol ?

Nuvectis Pharma, Inc. Common Stock is a US stock , located in Fort lee of Nj and trading under the symbol NVCT

What is Nuvectis Pharma, Inc. Common Stock stock quote today ?

Nuvectis Pharma, Inc. Common Stock stock price is $8.31 today.

Is Nuvectis Pharma, Inc. Common Stock stock public?

Yes, Nuvectis Pharma, Inc. Common Stock is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap